The Rhythm | Issue 13
Issue 13 | Week of 29 June 2026
No major cardiology congress fell this week, so the most consequential evidence arrived through journal publication. The thread running through it was time and trust: which of our habits hold up over the long run, which can be safely let go, and which remain promising ideas rather than proof.
Cardiology Intelligence Briefing: continue, withdraw, or trust over time
This was a quieter week for cardiology, but not an empty one. The strongest evidence gathered around the same practical question from different directions: what can be trusted to last, what can safely be reduced, and what still belongs in the category of promise rather than proof.
The most reassuring answer came from durability. As transcatheter valve replacement moves into younger and lower-risk patients, the unresolved concern has always been time. Seven-year follow-up showed no evident durability penalty for the transcatheter valve: structural valve deterioration, valve failure, and repeat valve intervention remained uncommon and tracked closely with surgery, with the main asymmetry being an excess of mostly subclinical valve thrombosis after transcatheter replacement, rarely progressing to failure.1 That does not settle lifetime valve planning, but it does make the seven-year durability worry harder to sustain.
The clearest case for doing less came from antiplatelet therapy. In patients at high bleeding risk after stenting, abbreviated dual antiplatelet therapy reduced bleeding without a detectable increase in major ischaemic events overall, although the safety of stopping at one month remains less certain.3 The message is not that a shorter duration of therapy is always better. It is that in the right bleeding-prone patient, less treatment can mean less harm without an obvious trade-off.
Two papers showed why enthusiasm still needs restraint. An amyloid-depleting antibody moved imaging, biomarker, and patient-reported measures in the right direction, but in a tiny open-label extension without controlled evidence yet that patients live longer, avoid hospitalisation, or function better.2 And the risk carried by a stubborn genetic lipid appeared to depend partly on the inflammatory company it keeps, a finding that sharpens risk assessment without yet creating a new treatment decision.4
The least settled question was whether recovery permits withdrawal. After rhythm control and normalisation of ventricular function, stopping heart failure therapy was not shown to be safe; the trial only failed to detect harm.5 That distinction matters. A small pilot can show feasibility, but it cannot remove the default caution that has followed previous withdrawal studies in recovered cardiomyopathy.
The discipline of a thin week is to prefer what has been demonstrated over what feels biologically convincing. This week rewarded that discipline: trust the durable, reduce treatment only where the trade-off is proven, and keep promising biology in its proper place.
